Methods and compositions for preventing and treating auditory dysfunctions

Patent metadata

Field	Value
Publication number	US-9889107-B2
Application number	US-201615230257-A
Country	US
Kind code	B2
Filing date	Aug 5, 2016
Priority date	May 31, 2012
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.

First claim

What is claimed is:

1. A method of inhibiting the loss or death of the cells of the auditory system in a mammal comprising administering to said mammal an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester or a pharmaceutically acceptable salt thereof,
wherein the carboxy alkyl ester is selected from the group consisting of
(a) 3,4-O-dicaffeoylquinic acid,
(b) 3,5-O-dicaffeoylquinic acid,
(c) 1,3-O-dicaffeoylquinic acid,
(d) 4,5-O-dicaffeoylquinic acid,
(e) 1,5-O-dicaffeoylquinic acid,
(f) 3-O-feruloylquinic acid,
(g) 4-O-feruloylquinic acid,
(h) 5-O-feruloylquinic acid,
(i) 1-O-caffeoylquinic acid,
(j) 3-O-caffeoylquinic acid,
(k) 4-O-caffeoylquinic acid,
(l) 5-O-caffeoylquinic acid,
(m) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid,
(n) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid,
(o) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid,
(p) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid,
(q) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid,
(r) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid,
(s) cis-5-O-caffeoylquinic acid,
(t) 3-O-caffeoylquinic acid lactone, and
(u) 3-O-caffeoyl-4-O-feruloylquinic acid
and a pharmaceutically acceptable salt thereof so thereby inhibiting the loss or death of the cells of the auditory system in the mammal.

2. A method of inhibiting hearing loss in a mammal by inhibiting the loss or death of the cells of the auditory system by the method of claim 1 .

3. The method of claim 1 , wherein administration of the composition is effected prior to an insult that can damage the auditory system.

4. The method of claim 3 , wherein the composition is administered prophylactically over a period of days, weeks, or months.

5. The method of claim 1 , wherein the active agent, is less than or equal to 10,000 daltons.

6. The method of claim 1 , wherein the active agent, is hydrophilic.

7. The method of claim 1 , wherein said composition further comprises an aqueous extract from Uncaria tomentosa.

8. The method of claim 7 , wherein the aqueous extract is an aqueous extract from Uncaria tomentosa bark.

9. The method of claim 8 , wherein the aqueous extract from Uncaria tomentosa bark comprises an active agent of less than or equal to 10,000 daltons.

10. The method of claim 1 , wherein the composition is formulated for administration selected from the group consisting of auricular, oral, parenteral, intraperitoneal, local, buccal, nasal, and topical administration.

11. The method of claim 1 , wherein said composition is an aqueous extract from Uncaria tomentosa.

12. The method of claim 11 , wherein the aqueous extract is an aqueous extract from Uncaria tomentosa bark.

13. The method of claim 12 , wherein the aqueous extract from Uncaria tomentosa bark comprises an active agent of less than or equal to 10,000 daltons.

14. The method of claim 1 , wherein said composition is in the form of a liquid, tablet or capsule.

Assignees

• Us Veterans Affairs

Inventors

• Guthrie Oneil W

Classifications

• A61K31/215

  of carboxylic acids · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/216 Primary

  of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title

• A61K31/365

  Lactones · CPC title

• A61K36/74

  Rubiaceae (Madder family) · CPC title